OncoTherapy Science, Inc. (4564.T)
JPY 25.0
(8.7%)
JPY 25.0
(8.7%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 867.27 Million JPY | -42.62% |
| 2022 | 1.51 Billion JPY | -43.71% |
| 2021 | 2.68 Billion JPY | -20.28% |
| 2020 | 3.36 Billion JPY | -33.8% |
| 2019 | 5.08 Billion JPY | -5.2% |
| 2018 | 5.36 Billion JPY | -33.09% |
| 2017 | 8.02 Billion JPY | -24.27% |
| 2016 | 10.59 Billion JPY | -22.47% |
| 2015 | 13.66 Billion JPY | -17.73% |
| 2014 | 16.6 Billion JPY | -10.61% |
| 2013 | 18.57 Billion JPY | 60.95% |
| 2012 | 11.54 Billion JPY | -9.24% |
| 2011 | 12.71 Billion JPY | 13.62% |
| 2010 | 11.19 Billion JPY | 9.5% |
| 2009 | 10.22 Billion JPY | 12.95% |
| 2008 | 9.05 Billion JPY | -0.63% |
| 2007 | 9.1 Billion JPY | 3.83% |
| 2006 | 8.77 Billion JPY | -13.39% |
| 2005 | 10.12 Billion JPY | -7.88% |
| 2004 | 10.99 Billion JPY | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 1.26 Billion JPY | 45.74% |
| 2023 Q3 | 931.16 Million JPY | -20.26% |
| 2023 FY | 867.27 Million JPY | -42.62% |
| 2023 Q4 | 867.27 Million JPY | -6.86% |
| 2023 Q2 | 1.16 Billion JPY | -8.45% |
| 2023 Q1 | 1.27 Billion JPY | -15.61% |
| 2022 Q1 | 2.04 Billion JPY | -23.93% |
| 2022 Q2 | 1.68 Billion JPY | -17.65% |
| 2022 Q3 | 1.44 Billion JPY | -14.15% |
| 2022 FY | 1.51 Billion JPY | -43.71% |
| 2022 Q4 | 1.51 Billion JPY | 4.67% |
| 2021 Q3 | 2.89 Billion JPY | -22.63% |
| 2021 Q4 | 2.68 Billion JPY | -7.16% |
| 2021 Q2 | 3.73 Billion JPY | 3.97% |
| 2021 FY | 2.68 Billion JPY | -20.28% |
| 2021 Q1 | 3.59 Billion JPY | 6.75% |
| 2020 Q4 | 3.36 Billion JPY | -9.69% |
| 2020 FY | 3.36 Billion JPY | -33.8% |
| 2020 Q1 | 4.57 Billion JPY | -10.01% |
| 2020 Q3 | 3.72 Billion JPY | -10.19% |
| 2020 Q2 | 4.15 Billion JPY | -9.31% |
| 2019 Q3 | 4.86 Billion JPY | -1.13% |
| 2019 Q2 | 4.92 Billion JPY | -4.45% |
| 2019 Q4 | 5.08 Billion JPY | 4.56% |
| 2019 FY | 5.08 Billion JPY | -5.2% |
| 2019 Q1 | 5.15 Billion JPY | -4.03% |
| 2018 Q1 | 7.21 Billion JPY | -10.0% |
| 2018 Q4 | 5.36 Billion JPY | -7.0% |
| 2018 Q3 | 5.77 Billion JPY | -7.68% |
| 2018 FY | 5.36 Billion JPY | -33.09% |
| 2018 Q2 | 6.25 Billion JPY | -13.41% |
| 2017 Q2 | 9.2 Billion JPY | -7.18% |
| 2017 FY | 8.02 Billion JPY | -24.27% |
| 2017 Q1 | 9.91 Billion JPY | -6.36% |
| 2017 Q3 | 8.84 Billion JPY | -3.89% |
| 2017 Q4 | 8.02 Billion JPY | -9.34% |
| 2016 Q4 | 10.59 Billion JPY | -7.49% |
| 2016 FY | 10.59 Billion JPY | -22.47% |
| 2016 Q3 | 11.45 Billion JPY | -5.36% |
| 2016 Q2 | 12.09 Billion JPY | -5.89% |
| 2016 Q1 | 12.85 Billion JPY | -5.91% |
| 2015 Q4 | 13.66 Billion JPY | -5.05% |
| 2015 Q2 | 15.16 Billion JPY | -6.07% |
| 2015 Q1 | 16.14 Billion JPY | -2.81% |
| 2015 FY | 13.66 Billion JPY | -17.73% |
| 2015 Q3 | 14.39 Billion JPY | -5.09% |
| 2014 Q4 | 16.6 Billion JPY | -2.94% |
| 2014 FY | 16.6 Billion JPY | -10.61% |
| 2014 Q3 | 17.11 Billion JPY | -2.89% |
| 2014 Q2 | 17.61 Billion JPY | -2.31% |
| 2014 Q1 | 18.03 Billion JPY | -2.92% |
| 2013 Q3 | 19.46 Billion JPY | -4.48% |
| 2013 Q4 | 18.57 Billion JPY | -4.55% |
| 2013 Q2 | 20.37 Billion JPY | 91.53% |
| 2013 FY | 18.57 Billion JPY | 60.95% |
| 2013 Q1 | 10.63 Billion JPY | -7.84% |
| 2012 FY | 11.54 Billion JPY | -9.24% |
| 2012 Q1 | 11.57 Billion JPY | -8.99% |
| 2012 Q2 | 11.26 Billion JPY | -2.71% |
| 2012 Q3 | 10.86 Billion JPY | -3.52% |
| 2012 Q4 | 11.54 Billion JPY | 6.24% |
| 2011 Q1 | 10.26 Billion JPY | -8.26% |
| 2011 Q2 | 9.76 Billion JPY | -4.95% |
| 2011 Q3 | 9.27 Billion JPY | -5.02% |
| 2011 Q4 | 12.71 Billion JPY | 37.19% |
| 2011 FY | 12.71 Billion JPY | 13.62% |
| 2010 Q1 | 9.6 Billion JPY | -6.06% |
| 2010 Q3 | 10.74 Billion JPY | 6.08% |
| 2010 Q4 | 11.19 Billion JPY | 4.18% |
| 2010 FY | 11.19 Billion JPY | 9.5% |
| 2010 Q2 | 10.12 Billion JPY | 5.47% |
| 2009 Q4 | 10.22 Billion JPY | 18.38% |
| 2009 FY | 10.22 Billion JPY | 12.95% |
| 2009 Q3 | 8.63 Billion JPY | 0.0% |
| 2008 FY | 9.05 Billion JPY | -0.63% |
| 2008 Q4 | 9.05 Billion JPY | 0.0% |
| 2007 FY | 9.1 Billion JPY | 3.83% |
| 2006 FY | 8.77 Billion JPY | -13.39% |
| 2005 FY | 10.12 Billion JPY | -7.88% |
| 2004 FY | 10.99 Billion JPY | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 6.58 Billion JPY | 86.838% |
| PRISM BioLab Co.,LTD | 1.21 Billion JPY | 28.409% |
| GNI Group Ltd. | 62.39 Billion JPY | 98.61% |
| Linical Co., Ltd. | 18.53 Billion JPY | 95.322% |
| Trans Genic Inc. | 9.81 Billion JPY | 91.16% |
| MEDINET Co., Ltd. | 5.63 Billion JPY | 84.607% |
| Soiken Holdings Inc. | 6.94 Billion JPY | 87.514% |
| Cytori Cell Research Institute, Inc. | 5.81 Billion JPY | 85.089% |
| AnGes, Inc. | 28.89 Billion JPY | 96.998% |
| Nxera Pharma Co., Ltd. | 157.19 Billion JPY | 99.448% |
| Immuno-Biological Laboratories Co., Ltd. | 1.61 Billion JPY | 46.418% |
| NanoCarrier Co., Ltd. | 5.07 Billion JPY | 82.898% |
| Carna Biosciences, Inc. | 4.34 Billion JPY | 80.062% |
| CanBas Co., Ltd. | 2.43 Billion JPY | 64.352% |
| D. Western Therapeutics Institute, Inc. | 2.37 Billion JPY | 63.458% |
| RaQualia Pharma Inc. | 6.93 Billion JPY | 87.486% |
| Chiome Bioscience Inc. | 1.75 Billion JPY | 50.483% |
| Kidswell Bio Corporation | 5.08 Billion JPY | 82.946% |
| PeptiDream Inc. | 67.12 Billion JPY | 98.708% |
| Oncolys BioPharma Inc. | 2.04 Billion JPY | 57.499% |
| Ribomic Inc. | 3.54 Billion JPY | 75.551% |
| SanBio Company Limited | 5.04 Billion JPY | 82.817% |
| Healios K.K. | 15.15 Billion JPY | 94.277% |
| BrightPath Biotherapeutics Co., Ltd. | 1.23 Billion JPY | 29.505% |
| Kubota Pharmaceutical Holdings Co., Ltd. | 3.01 Billion JPY | 71.244% |
| Delta-Fly Pharma, Inc. | 1.47 Billion JPY | 41.168% |
| StemRIM | 9.08 Billion JPY | 90.449% |
| CellSource Co., Ltd. | 6.87 Billion JPY | 87.394% |
| FunPep Company Limited | 2.49 Billion JPY | 65.186% |
| Kringle Pharma, Inc. | 2.61 Billion JPY | 66.881% |
| Stella Pharma Corporation | 3.82 Billion JPY | 77.3% |
| TMS Co., Ltd. | 3.55 Billion JPY | 75.602% |
| Noile-Immune Biotech Inc. | 5.77 Billion JPY | 84.993% |
| Cuorips Inc. | 6.18 Billion JPY | 85.977% |
| K Pharma,Inc. | 3.31 Billion JPY | 73.829% |
| Takara Bio Inc. | 123.2 Billion JPY | 99.296% |
| ReproCELL Incorporated | 9.05 Billion JPY | 90.42% |
| PhoenixBio Co., Ltd. | 2.71 Billion JPY | 68.06% |
| StemCell Institute Inc. | 6.54 Billion JPY | 86.745% |
| Japan Tissue Engineering Co., Ltd. | 6.98 Billion JPY | 87.59% |
| CellSeed Inc. | 2.46 Billion JPY | 64.827% |